Recent advances in the management of pulmonary sarcomatoid carcinoma

Elaine Shum, Matthew Stuart, Alain Borczuk, Feng Wang, Haiying Cheng, Balazs Halmos

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a unique and biologically fascinating group of poorly differentiated non-small cell lung cancer (NSCLC), however it is highly aggressive with poor overall survival compared to other types of NSCLC. Radical surgery remains the standard of care for early localized disease but this has shown to result in high recurrence rates. Traditional palliative chemotherapy is associated with poor response in advanced/metastatic PSC. Recent comprehensive genetic studies and clinical observations are starting to elucidate the key oncogenic underpinnings of PSC. In particular, the recent identification of frequent genetic alterations of the MET gene leading to exon 14 skipping have yielded actionable targets for intervention with available MET inhibitors for a subset of PSC patients. Immunotherapy against immune checkpoints, such as anti-PD1/PD-L1 agents, have also raised great interest for the management of PSC. A growing understanding of the molecular pathogenesis of PSC is rapidly yielding novel approaches for the treatment of this deadly malignancy.

Original languageEnglish (US)
Pages (from-to)407-416
Number of pages10
JournalExpert Review of Respiratory Medicine
Volume10
Issue number4
DOIs
StatePublished - Apr 2 2016

Fingerprint

Carcinoma
Lung
Non-Small Cell Lung Carcinoma
Standard of Care
Immunotherapy
Exons
Recurrence
Drug Therapy
Survival
Genes
Neoplasms
Therapeutics

Keywords

  • Chemotherapy
  • immunotherapy
  • KRAS
  • lung cancer
  • MET
  • Pulmonary sarcomatoid carcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health

Cite this

Recent advances in the management of pulmonary sarcomatoid carcinoma. / Shum, Elaine; Stuart, Matthew; Borczuk, Alain; Wang, Feng; Cheng, Haiying; Halmos, Balazs.

In: Expert Review of Respiratory Medicine, Vol. 10, No. 4, 02.04.2016, p. 407-416.

Research output: Contribution to journalArticle

Shum, Elaine ; Stuart, Matthew ; Borczuk, Alain ; Wang, Feng ; Cheng, Haiying ; Halmos, Balazs. / Recent advances in the management of pulmonary sarcomatoid carcinoma. In: Expert Review of Respiratory Medicine. 2016 ; Vol. 10, No. 4. pp. 407-416.
@article{beb90231150a42b79deb27fea481b664,
title = "Recent advances in the management of pulmonary sarcomatoid carcinoma",
abstract = "Pulmonary sarcomatoid carcinoma (PSC) is a unique and biologically fascinating group of poorly differentiated non-small cell lung cancer (NSCLC), however it is highly aggressive with poor overall survival compared to other types of NSCLC. Radical surgery remains the standard of care for early localized disease but this has shown to result in high recurrence rates. Traditional palliative chemotherapy is associated with poor response in advanced/metastatic PSC. Recent comprehensive genetic studies and clinical observations are starting to elucidate the key oncogenic underpinnings of PSC. In particular, the recent identification of frequent genetic alterations of the MET gene leading to exon 14 skipping have yielded actionable targets for intervention with available MET inhibitors for a subset of PSC patients. Immunotherapy against immune checkpoints, such as anti-PD1/PD-L1 agents, have also raised great interest for the management of PSC. A growing understanding of the molecular pathogenesis of PSC is rapidly yielding novel approaches for the treatment of this deadly malignancy.",
keywords = "Chemotherapy, immunotherapy, KRAS, lung cancer, MET, Pulmonary sarcomatoid carcinoma, Targeted therapy",
author = "Elaine Shum and Matthew Stuart and Alain Borczuk and Feng Wang and Haiying Cheng and Balazs Halmos",
year = "2016",
month = "4",
day = "2",
doi = "10.1586/17476348.2016.1157475",
language = "English (US)",
volume = "10",
pages = "407--416",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Recent advances in the management of pulmonary sarcomatoid carcinoma

AU - Shum, Elaine

AU - Stuart, Matthew

AU - Borczuk, Alain

AU - Wang, Feng

AU - Cheng, Haiying

AU - Halmos, Balazs

PY - 2016/4/2

Y1 - 2016/4/2

N2 - Pulmonary sarcomatoid carcinoma (PSC) is a unique and biologically fascinating group of poorly differentiated non-small cell lung cancer (NSCLC), however it is highly aggressive with poor overall survival compared to other types of NSCLC. Radical surgery remains the standard of care for early localized disease but this has shown to result in high recurrence rates. Traditional palliative chemotherapy is associated with poor response in advanced/metastatic PSC. Recent comprehensive genetic studies and clinical observations are starting to elucidate the key oncogenic underpinnings of PSC. In particular, the recent identification of frequent genetic alterations of the MET gene leading to exon 14 skipping have yielded actionable targets for intervention with available MET inhibitors for a subset of PSC patients. Immunotherapy against immune checkpoints, such as anti-PD1/PD-L1 agents, have also raised great interest for the management of PSC. A growing understanding of the molecular pathogenesis of PSC is rapidly yielding novel approaches for the treatment of this deadly malignancy.

AB - Pulmonary sarcomatoid carcinoma (PSC) is a unique and biologically fascinating group of poorly differentiated non-small cell lung cancer (NSCLC), however it is highly aggressive with poor overall survival compared to other types of NSCLC. Radical surgery remains the standard of care for early localized disease but this has shown to result in high recurrence rates. Traditional palliative chemotherapy is associated with poor response in advanced/metastatic PSC. Recent comprehensive genetic studies and clinical observations are starting to elucidate the key oncogenic underpinnings of PSC. In particular, the recent identification of frequent genetic alterations of the MET gene leading to exon 14 skipping have yielded actionable targets for intervention with available MET inhibitors for a subset of PSC patients. Immunotherapy against immune checkpoints, such as anti-PD1/PD-L1 agents, have also raised great interest for the management of PSC. A growing understanding of the molecular pathogenesis of PSC is rapidly yielding novel approaches for the treatment of this deadly malignancy.

KW - Chemotherapy

KW - immunotherapy

KW - KRAS

KW - lung cancer

KW - MET

KW - Pulmonary sarcomatoid carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84961200723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961200723&partnerID=8YFLogxK

U2 - 10.1586/17476348.2016.1157475

DO - 10.1586/17476348.2016.1157475

M3 - Article

AN - SCOPUS:84961200723

VL - 10

SP - 407

EP - 416

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 4

ER -